BALVERSA (erdafitinib): Educational Program – May 13th
Loading Map....
You are cordially invited to attend the educational program: BALVERSA (erdafitinib)
The first and only approved second-line oral targeted therapy to treat locally advanced metastatic urothelial carcinoma expressing FGFR3 altering/mutations.
Presented by: Dr. Arash Rezazadeh
When: Tuesday, May 13, 2025 @ 6pm.
Where: Vina Enoteca, 700 Welch Road, Palo Alto, CA 94304
RSVP: Jane Lafontaine (650) 773-1416 jlafonta@its.jnj.com